Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 5Gynecologic 3Genitourinary 2Gastrointestinal 2Sarcoma 1Head & Neck 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Ovarian Neoplasms 1Neoplastic Syndromes, Hereditary 1Hematologic Neoplasms 1Fanconi Anemia, Complementation Group D1 1Cytopenia 1Congenital Bone Marrow Failure Syndromes 1Breast Neoplasms 1Bone Marrow Failure Disorders 1

Interventions

Epoetin Alfa 6olaparib 5pegfilgrastim 3Filgrastim 3Carboplatin 3pembrolizumab 2pegylated granulocyte colony-stimulating factor 2palbociclib 2abemaciclib 2Tretinoin 2venetoclax 1trametinib 1talazoparib 1stinging nettle lectin 1ruxolitinib 1ribociclib 1regorafenib 1ponatinib 1pertuzumab 1peppermint oil 1neratinib 1lorlatinib 1lenvatinib 1idelalisib 1fludarabine phosphate 1enzalutamide 1entrectinib 1enasidenib 1durvalumab 1dehydroftorafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Genetic Counseling × Classical hematology × Clear all
NCT00165152 2012-08-09

Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing

Dana-Farber Cancer Institute

Phase NA Completed
150 enrolled
BreastClassical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡